Two new clinical trials for ExCellThera lead technology, ECT-001

IRICoR is pleased with the announcement made by ExCellThera, a clinical stage biotechnology company, which is result of its collaboration with the Center for Commercialization of Regenerative Medicine (CCRM), regarding the clearance by FDA and Health Canada for two new clinical trials for using its innovative ECT-001 technology in the treatment of leukemia.

ExCellThera designs product and service solutions based on the novel intellectual property dealing with the technique of stem cells’ expansion, developed by Dr. Guy Sauvageau at the IRIC, and Dr. Peter Zandstra at the University of Toronto’s Institute of Biomaterials and Biomedical Engineering. ExCellThera’s lead solution combines a proprietary small molecule, UM171, and an optimized culture system.

 

The US-based study will be conducted at the Fred Hutchinson Cancer Centre in Seattle, Washington, with the Canadian study principally taking place at the Maisonneuve-Rosemont Hospital in Montreal.

“This new milestone for ExCellThera, reached in a very short time, is a major breakthrough: only four years after its creation, its ECT-001 technology received the Orphan Drug Designation and the company will pursue two clinical trials for high-risk patients with leukemia,” said Dr. Nadine Beauger, CEO of IRICoR. “We are delighted with the progress made by ExCellThera, which concretely illustrates the value of IRICoR in its leading role as an accelerator of promising projects targeting the treatment of diseases with unmet medical needs.”

 

To read the ExCellThera press release, click here.